These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36343410)

  • 21. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
    Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
    J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel FFA1 (GPR40) agonists containing spirocyclic periphery: polar azine periphery as a driver of potency.
    Krasavin M; Lukin A; Bagnyukova D; Zhurilo N; Zahanich I; Zozulya S
    J Enzyme Inhib Med Chem; 2017 Dec; 32(1):29-36. PubMed ID: 27781494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
    Chen C; Li H; Long YQ
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5603-5612. PubMed ID: 27825762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of novel potent GPR40 agonists containing imidazo[1,2-a]pyridine core as antidiabetic agents.
    Ye Z; Liu C; Zou F; Cai Y; Chen B; Zou Y; Mo J; Han T; Huang W; Qiu Q; Qian H
    Bioorg Med Chem; 2020 Jul; 28(13):115574. PubMed ID: 32546302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents.
    Zhou Z; Ren Q; Jiao S; Cai Z; Geng X; Deng L; Wang B; Hu L; Zhang L; Yang Y; Li Z
    Eur J Med Chem; 2022 Feb; 229():114061. PubMed ID: 34954593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and biological evaluation of novel potent FFA1 agonists containing 2,3-dihydrobenzo[b][1,4]dioxine.
    Kong D; Guo S; Yang Y; Guo B; Xie X; Hu W
    Bioorg Med Chem Lett; 2019 Mar; 29(6):848-852. PubMed ID: 30685095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes.
    Araki T; Hirayama M; Hiroi S; Kaku K
    Diabetes Obes Metab; 2012 Mar; 14(3):271-8. PubMed ID: 22051148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.
    Christiansen E; Urban C; Grundmann M; Due-Hansen ME; Hagesaether E; Schmidt J; Pardo L; Ullrich S; Kostenis E; Kassack M; Ulven T
    J Med Chem; 2011 Oct; 54(19):6691-703. PubMed ID: 21854074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes.
    Bharate SB; Nemmani KV; Vishwakarma RA
    Expert Opin Ther Pat; 2009 Feb; 19(2):237-64. PubMed ID: 19441920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis and biological activity of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists.
    Li Z; Wang X; Xu X; Yang J; Xia W; Zhou X; Huang W; Qian H
    Bioorg Med Chem; 2015 Nov; 23(22):7158-64. PubMed ID: 26482570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of phenylsulfonyl acetic acid derivatives with improved efficacy and safety as potent free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
    Li Z; Liu C; Xu X; Qiu Q; Su X; Dai Y; Yang J; Li H; Shi W; Liao C; Pan M; Huang W; Qian H
    Eur J Med Chem; 2017 Sep; 138():458-479. PubMed ID: 28689096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-based optimization of free fatty acid receptor 1 agonists bearing thiazole scaffold.
    Li Z; Xu X; Hou J; Wang S; Jiang H; Zhang L
    Bioorg Chem; 2018 Apr; 77():429-435. PubMed ID: 29433092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents.
    Lin DC; Zhang J; Zhuang R; Li F; Nguyen K; Chen M; Tran T; Lopez E; Lu JY; Li XN; Tang L; Tonn GR; Swaminath G; Reagan JD; Chen JL; Tian H; Lin YJ; Houze JB; Luo J
    PLoS One; 2011; 6(11):e27270. PubMed ID: 22087278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent Advances in Development of GPR40 Modulators (FFA1/FFAR1): An Emerging Target for Type 2 Diabetes.
    Sharma N; Bhagat S; Chundawat TS
    Mini Rev Med Chem; 2017; 17(11):947-958. PubMed ID: 28117025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A New Pain Regulatory System via the Brain Long Chain Fatty Acid Receptor GPR40/FFA1 Signal].
    Nakamoto K
    Yakugaku Zasshi; 2017; 137(2):199-204. PubMed ID: 28154332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold.
    Krasavin M; Lukin A; Zhurilo N; Kovalenko A; Zahanich I; Zozulya S; Moore D; Tikhonova IG
    Bioorg Med Chem; 2016 Jul; 24(13):2954-2963. PubMed ID: 27229618
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development.
    Li Z; Qiu Q; Geng X; Yang J; Huang W; Qian H
    Expert Opin Investig Drugs; 2016 Aug; 25(8):871-90. PubMed ID: 27171154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties.
    Christiansen E; Due-Hansen ME; Urban C; Grundmann M; Schröder R; Hudson BD; Milligan G; Cawthorne MA; Kostenis E; Kassack MU; Ulven T
    J Med Chem; 2012 Jul; 55(14):6624-8. PubMed ID: 22724451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nitric oxide donor-based FFA1 agonists: Design, synthesis and biological evaluation as potential anti-diabetic and anti-thrombotic agents.
    Li Z; Xu X; Liu R; Deng F; Zeng X; Zhang L
    Bioorg Med Chem; 2018 Aug; 26(15):4560-4566. PubMed ID: 30082106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold.
    Li Z; Liu C; Yang J; Zhou J; Ye Z; Feng D; Yue N; Tong J; Huang W; Qian H
    Eur J Med Chem; 2019 Oct; 179():608-622. PubMed ID: 31279294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.